Isaac Israel CEO @isaac2199 Of Kitov Pharmaceuticals Discusses CM-24 Monoclonal Antibody: Plan To Initiate A Clinical Trial In Combination With Nivolumab, Initially Selecting NSCLC Patients.
CM-24 Monoclonal Antibody: Plan To Initiate A Clinical Trial In Combination With Nivolumab, Initially Selecting NSCLC Patients
